Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
Status:
Active, not recruiting
Trial end date:
2028-04-05
Target enrollment:
Participant gender:
Summary
This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of
belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic
lupus erythematosus